Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Blood Research · 2024-12 · 59 (1)
DOI: 10.1007/s44313-024-00039-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 18.10.2024. Verfasst von Sung Eun Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kyungpook National University Hospital, Kyungpook National University Chilgok Hospital, 807 Hoguk-Ro, Buk-Gu, Daegu, 41404,…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Purpose
Hemophilia A is a genetic disorder characterized by a lack of factor VIII (FVIII). Emicizumab, a recombinant humanized bispecific monoclonal antibody, mimics the function of FVIII. In this article, we present data on an initial real-world evaluation of emicizumab use in Korean children with severe hemophilia A without inhibitors.
Methods
This study was conducted from June 2020 to March 2024 at 4 centers in Korea. The participants were pediatric patients with severe hemophilia A without inhibitors who had received emicizumab treatment for over 6 months. The mean and median annualized bleeding rates (ABRs) and mean and median annual joint bleeding rates (AJBRs) were compared.
Results
Each of the 21 patients in the study received an emicizumab loading regimen of 3 mg/kg weekly for 4 weeks, followed by a modified maintenance regimen of which 2 patients (9.5%) received a 1.5 mg/kg weekly dose, 3 patients (14.3%) received a 6 mg/kg dose every 4 weeks, and the remaining 16 patients (76.2%) received a 3 mg/kg dose every 2 weeks. Before emicizumab prophylaxis initiation, the mean and median ABRs for all patients were 7.04 (SD ± 5.83) and 6.52 (range 0–21.74), respectively. After receiving emicizumab treatment, the mean and mediam ABRs decreased to 0.41 and zero, respectively. Additionally, 85.7% of the patients achieved no bleeding events within 6 months of starting the treatment.
Conclusion
These first real-world data in Korea indicate that emicizumab is effective and safe for pediatric patients with severe hemophilia A without inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Kyungpook National University Hospital, Kyungpook National University Chilgok Hospital, 807 Hoguk-Ro, Buk-Gu, Daegu, 41404, Republic of Korea.
- Department of Pediatrics, School of Medicine, Kyungpook National University, 680 Gukchaebosang-Ro, Jung-Gu, Daegu, 41944, Republic of Korea.
- Department of Pediatrics, Inha University Hospital, 27 Inhang-Ro, Jung-Gu, Incheon, 22332, Republic of Korea.
- Department of Pediatrics, Yonsei University Severance Children's Hospital, 50-1 Yonseiro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.
- Department of Pediatrics, Kyung Hee University Hospital at Gangdong, 892 Dongnam-Ro, Gangdong-Gu, Seoul, 05278, Republic of Korea. pysped@khu.ac.kr.
Zitieren
APA
Kim, S. E., Kim, J. Y., Park, J. A., Lyu, C. J., Hahn, S. M., Han, J. W., & Park, Y. S. (2024). Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors. Blood Research, 59(1). https://doi.org/10.1007/s44313-024-00039-1
Vancouver
Kim SE, Kim JY, Park JA, Lyu CJ, Hahn SM, Han JW, et al. Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors. Blood Research. 2024;59(1). doi:10.1007/s44313-024-00039-1
BibTeX
@article{Kim2024,
author = {Kim, Sung Eun and Kim, Ji Yoon and Park, Jeong A and Lyu, Chuhl Joo and Hahn, Seung Min and Han, Jung Woo and Park, Young Shil},
title = {Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors},
journal = {Blood Research},
year = {2024},
volume = {59},
number = {1},
doi = {10.1007/s44313-024-00039-1}
}
EUVIMED